

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
Application Number	09/974,781			
Filing Date	10 October 2001			
First Named Inventor	Michael G. Kahn			
Group Art Unit	2166			
Examiner Name	Unknown			
Attorney Docket Number	FSTK 1004-1			

OIPE  
FEB 1 1 2002  
U.S. PATENT & TRADEMARK OFFICE

Sheet	1	of	2
-------	---	----	---

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DBC	C1	DataEdge LLC. Indexes of Clinical Study Complexity, 1993-1999. In: Mathieu MP, editor. Parexel's Pharmaceutical R&D Statistical Sourcebook 2000. Waltham, MA: Parexel International Corp; 2000. p. 66.	
f	C2	DataEdge LLC. Indexes of Clinical Trial Costs Per Patient, 1993-1999. In: Mathieu MP, editor. Parexel's Pharmaceutical R&D Statistical Sourcebook 2000. Waltham, MA: Parexel International Corp; 2000. p. 67.	
f	C3	GROSSO W. E. et al.; "Knowledge Modeling at the Millennium (The Design and Evolution of Protégé-2000)," SMI Report Number: SMI-1999-0801 (1999), available at <a href="http://smi-web.stanford.edu/pubs/SMI_Abstracts/SMI-1999-0801.html">http://smi-web.stanford.edu/pubs/SMI_Abstracts/SMI-1999-0801.html</a> , visited 01/01/2000.	
f	C4	HOLFORD N. H. G.; KIMKO H. C.; MONTELEONE J. P. R., and PECK C. C.; "Simulation of Clinical Trials," Annu. Rev. Pharmacol. Toxicol. 2000, 40:209-34, 2000, Annual Reviews.	
f	C5	"ICH Harmonised Tripartite Guideline: General Considerations for Clinical Trials," International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use recommended for adoption on 17 July 1997, URL: <a href="http://www.ifpma.org/ich5e.html">www.ifpma.org/ich5e.html</a> , Accessed: 31 August 2001.	
f	C6	"ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice," International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use recommended for adoption on 1 May 1996, URL: <a href="http://www.ifpma.org/ich5e.html">www.ifpma.org/ich5e.html</a> , Accessed: 31 August 2001.	
f	C7	KROLL J. A.; DE BRUIN A.; GETZ K.; ESCHMANN K.; and ZISSON S.; "Study Conduct Delays are Getting Worse," In: Kroll JA, editor. An Industry In Evolution. Second ed. Boston, MA: CenterWatch; 1999. p. 99.	
f	C8	MUSEN M. A.; "Domain Ontologies in Software Engineering: Use of Protégé with the EON Architecture," Methods of Information in Medicine, F. K. Schattauer Verlagsgesellschaft mbH (1998); 37:540-50.	
f	C9	MUSEN M. A.; GENNARI J. H.; ERIKSSON H.; TU S. W.; and PUERTA A. R.; Protégé-II: Computer Support for Development of Intelligent Systems from Libraries of Components," MEDINFO 95 Proceedings. R. A. Greenes et al. (editors); 8(1):766-70.	
f	C10	MUSEN M. A.; ROHN J. A.; FAGAN L. M.; and SHORTLIFFE E. H.; "Knowledge Engineering for a Clinical Trial Advice System: Uncovering Errors in Protocol Specification," Report KSL-85-51, Proceedings AAMSI Congress 1986 (Levy, A.H. and Williams, B.T., eds.), pp. 24-27, Anaheim CA, May 1986.	
DBC	C11	SHEINER L. B. and STEIMER J. L.; "Pharmacokinetic/Pharmacodynamic Modeling in Drug Development," Annu. Rev. Pharmacol. Toxicol. 2000. 40:67-95, 2000, Annual Reviews.	

Examiner Signature		Date Considered	06/22/2006
--------------------	--	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known Application Number 09/974,781 Filing Date 10 October 2006 First Named Inventor Michael G. Kahn Group Art Unit 2166 Examiner Name Unknown Attorney Docket Number FSTK 1004-1	
Sheet	2	of	2		

[illegible]

Examiner Signature	Dilek Gbangha	Date Considered	06/22/2006
-----------------------	---------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/974,781
Filing Date	10 October 2001
First Named Inventor	Michael Kahn
Art. Unit	3626
Examiner Name	Dilek B. Cobanoglu
Attorney Docket Number	FSTK 1004-1

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DBC		Brown, et al., U.S. Patent Application No. 09/974,781, filed 10 October 2001, entitled Leveraging Interaction with a Community of Individuals." 84 pages	
		09201323	

Examiner  
Signature

Dilek B. Cobanoglu

Date  
Considered

06/22/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.